Louise Abbott: Targeting lung cancer screening on high risk groups is central to the value case for national lung cancer screening programmes.
Louise Abbott, Head of International Practice at Evoke Incisive Health, made the following post on LinkedIn:
“Targeting lung cancer screening on high risk groups is central to the value case for national lung cancer screening programmes.
But what do we know about how these work in the real world?
Great session at WCLC23 on real world studies on lung cancer screening – some key take aways:
• The benefit of lung cancer screening (life years saved) far exceeds that of smoking cessation, even for current smokers
• People who formally smoked retain a significant risk of developing lung cancer- calling into question the inclusion of 10/15 YSQ
• The inclusion of years of smoking rather than pack history (intensity of smoking) in USPSTF-2021 could increase the proportion of people eligible for screening from different population groups
• Applying AI to risk-based lung cancer screening models (rather than risk factor-based screening criteria like USPSTF-2021) increases predictive performance and could make them simpler to use in more screening settings.
As more governments look to introduce screening programmes its important we learn from real world evidence as well as the key screening trials.”
Source: Louise Abbott / LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023